Fuller & Thaler Asset Management Inc. Has $40.94 Million Stock Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Fuller & Thaler Asset Management Inc. increased its stake in Collegium Pharmaceutical by 1.4% during the first quarter, owning 4.27% of the company worth approximately $40.9 million.
• Collegium Pharmaceutical has initiated a stock buyback plan allowing for the repurchase of up to $150 million of its shares, which represents 15.4% of its outstanding shares, indicating the board's belief in the stock's undervaluation.
• Several analysts have upgraded their ratings on Collegium Pharmaceutical, with HC Wainwright setting a "strong-buy" rating and a price target of $44.00.

Fuller & Thaler Asset Management Inc. increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,371,448 shares of the specialty pharmaceutical company's stock after acquiring an additional 19,568 shares during the period. Fuller & Thaler Asset Management Inc. owned about 4.27% of Collegium Pharmaceutical worth $40,938,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. MetLife Investment Management LLC grew its holdings in Collegium Pharmaceutical by 8.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after acquiring an additional 1,558 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Collegium Pharmaceutical during the first quarter worth approximately $244,000. Janney Montgomery Scott LLC acquired a new position in shares of Collegium Pharmaceutical during the first quarter worth approximately $439,000. GAMMA Investing LLC grew its stake in shares of Collegium Pharmaceutical by 8,947.4% during the first quarter. GAMMA Investing LLC now owns 17,552 shares of the specialty pharmaceutical company's stock valued at $524,000 after purchasing an additional 17,358 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Collegium Pharmaceutical by 38.8% in the fourth quarter. Millennium Management LLC now owns 185,918 shares of the specialty pharmaceutical company's stock valued at $5,327,000 after purchasing an additional 51,972 shares in the last quarter.

Collegium Pharmaceutical Trading Down 1.0%

Shares of NASDAQ COLL traded down $0.41 during midday trading on Friday, reaching $39.11. 447,830 shares of the stock were exchanged, compared to its average volume of 413,800. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 37.61 and a beta of 0.68. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10. The business has a 50-day simple moving average of $32.42 and a two-hundred day simple moving average of $30.05.

Collegium Pharmaceutical declared that its Board of Directors has authorized a stock buyback plan on Monday, July 7th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the specialty pharmaceutical company to buy up to 15.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on COLL. Piper Sandler restated a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. HC Wainwright upgraded Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 target price for the company in a research report on Monday, August 11th. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $42.33.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 16,389 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the completion of the transaction, the executive vice president directly owned 103,613 shares of the company's stock, valued at $3,959,052.73. This trade represents a 13.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Gordon Freund sold 11,659 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the completion of the sale, the director directly owned 23,129 shares in the company, valued at approximately $794,712.44. This represents a 33.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,915 shares of company stock valued at $1,614,825 in the last quarter. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.